Intrexon
Intrexon Completes $230M Public Offering
The firm sold 5,609,756 shares of its common stock at $41 per share. Proceeds will be used for general corporate purposes and strategic acquisitions or investments.
Intrexon Prices Public Offering Targeting $200M
The synthetic biology firm is offering about 4.9 million shares of its common stock at $41 per share.
Intrexon to Complete Acquisition of Exemplar Genetics
Intrexon seeks to buy the remaining 49 percent stake in the firm, which creates animal models of human diseases in miniature pigs.
Intrexon Buying Medistem for $26M
NEW YORK (GenomeWeb News) – Intrexon today announced an agreement to acquire adult stem cell technology firm Medistem for about $26 million.
Intrexon Reports Sharp Rise in Q3 Revenues
NEW YORK (GenomeWeb News) – Reporting for the first time as a public company, synthetic biology company Intrexon said after the close of the market on Thursday that revenues in its third quarter more than doubled year over year.
Sep 20, 2013
Intrexon's Q2 Revenues Rise Sharply as Loss Declines
Aug 14, 2013
Intrexon Closes IPO Raising $184M
May 31, 2011
Intrexon Raises $100M in Series E Round
Apr 25, 2011
Intrexon Raises $66.9M
Feb 1, 2011
Intrexon Buys Agarigen, Creates AgBio Division
Jan 15, 2010
People in the News: Jan 15, 2010
Jan 8, 2010